Q-omics provides the consensus-scored DUSP26 profile across patient tissues and cancer cell-line models. DUSP26 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, DUSP26 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, DUSP26 RNA expression shows 22,389 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight SKCM, COAD, and GBM as cancer lineages where DUSP26 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DUSP26 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DUSP26 survival associations across molecular data types. DUSP26 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DUSP26 RNA expression–survival associations across cancer types. High DUSP26 expression shows unfavorable associations in LUSC, but favorable associations in SKCM, BRCA, LGG, LUAD and PAAD. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify SKCM as the clearest survival context for DUSP26 RNA expression.
This table summarizes DUSP26 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for DUSP26. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DUSP26 shows lower tumor expression in COAD, KIRP, KIRC, KICH, HNSC and LUSC. The COAD box plot shows higher DUSP26 RNA expression in normal versus tumor tissue (log2 FC = −1.440, t-test p < 0.001).
This table shows molecular features associated with DUSP26 in patient tissues and cancer cell lines. In patient samples, DUSP26 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, DUSP26 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BONE and OVARY.
